These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28339817)

  • 1. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Ledingham J; Gullick N; Irving K; Gorodkin R; Aris M; Burke J; Gordon P; Christidis D; Galloway S; Hayes E; Jeffries A; Mercer S; Mooney J; van Leuven S; Galloway J;
    Rheumatology (Oxford); 2017 Jun; 56(6):865-868. PubMed ID: 28339817
    [No Abstract]   [Full Text] [Related]  

  • 2. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
    Flint J; Panchal S; Hurrell A; van de Venne M; Gayed M; Schreiber K; Arthanari S; Cunningham J; Flanders L; Moore L; Crossley A; Purushotham N; Desai A; Piper M; Nisar M; Khamashta M; Williams D; Gordon C; Giles I;
    Rheumatology (Oxford); 2016 Sep; 55(9):1693-7. PubMed ID: 26750124
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy: A fine conception -- BSR/BHPR guidelines on drugs in pregnancy.
    Sammaritano LR; Bermas BL
    Nat Rev Rheumatol; 2016 Apr; 12(4):197-8. PubMed ID: 26984054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study.
    Vroom F; van Roon EN; van den Berg PB; Brouwers JR; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):52-61. PubMed ID: 17948319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.
    Chakravarty K; McDonald H; Pullar T; Taggart A; Chalmers R; Oliver S; Mooney J; Somerville M; Bosworth A; Kennedy T; ;
    Rheumatology (Oxford); 2008 Jun; 47(6):924-5. PubMed ID: 16940305
    [No Abstract]   [Full Text] [Related]  

  • 6. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice.
    Flint J; Panchal S; Hurrell A; van de Venne M; Gayed M; Schreiber K; Arthanari S; Cunningham J; Flanders L; Moore L; Crossley A; Purushotham N; Desai A; Piper M; Nisar M; Khamashta M; Williams D; Gordon C; Giles I;
    Rheumatology (Oxford); 2016 Sep; 55(9):1698-702. PubMed ID: 26750125
    [No Abstract]   [Full Text] [Related]  

  • 8. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.
    Bhalla AK; Samaranayaka M
    Rheumatology (Oxford); 2008 Oct; 47(10):1591; author reply 1591. PubMed ID: 18676499
    [No Abstract]   [Full Text] [Related]  

  • 10. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.
    Pincus T; Furer V; Sokka T
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S68-79. PubMed ID: 21044437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Ledingham J; Gullick N; Irving K; Gorodkin R; Aris M; Burke J; Gordon P; Christidis D; Galloway S; Hayes E; Jeffries A; Mercer S; Mooney J; van Leuven S; Galloway J
    Rheumatology (Oxford); 2017 Dec; 56(12):2257. PubMed ID: 29029272
    [No Abstract]   [Full Text] [Related]  

  • 12. How and when to use DMARDs.
    Simmons S
    Nurse Pract; 2010 Aug; 35(8):12-4. PubMed ID: 20644444
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
    Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Pakozdi A; Tahir H
    Rheumatol Adv Pract; 2017; 1(1):rkx009. PubMed ID: 31431947
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of vaccination in rheumatic disease.
    Wong PKK; Hanrahan P
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):720-734. PubMed ID: 31427051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
    Martin JJ
    Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.
    Russell MD; Dey M; Flint J; Davie P; Allen A; Crossley A; Frishman M; Gayed M; Hodson K; Khamashta M; Moore L; Panchal S; Piper M; Reid C; Saxby K; Schreiber K; Senvar N; Tosounidou S; van de Venne M; Warburton L; Williams D; Yee CS; Gordon C; Giles I;
    Rheumatology (Oxford); 2023 Apr; 62(4):e48-e88. PubMed ID: 36318966
    [No Abstract]   [Full Text] [Related]  

  • 20. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.
    Russell MD; Dey M; Flint J; Davie P; Allen A; Crossley A; Frishman M; Gayed M; Hodson K; Khamashta M; Moore L; Panchal S; Piper M; Reid C; Saxby K; Schreiber K; Senvar N; Tosounidou S; van de Venne M; Warburton L; Williams D; Yee CS; Gordon C; Giles I;
    Rheumatology (Oxford); 2023 Apr; 62(4):1370-1387. PubMed ID: 36318965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.